Cost-effectiveness of insulin analogues for diabetes mellitus

CMAJ. Canadian Medical Association Journal

Volumn 180, Issue 4, 2009, Pages 400-407

  Cameron, Chris G ^a   Bennett Bpharm, Heather A ^a  

^a CANADIAN AGENCY FOR DRUGS AND TECHNOLOGIES IN HEALTH   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; ISOPHANE INSULIN;

ANGINA PECTORIS; ARTICLE; BLINDNESS; CATARACT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; FOOT ULCER; GANGRENE; HEALTH CARE COST; HEART INFARCTION; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KETOACIDOSIS; KIDNEY DISEASE; MEDICAL INFORMATION SYSTEM; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PERIPHERAL VASCULAR DISEASE; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STROKE;

EID: 61449180331     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.081180     Document Type: Article

References (61)

1. Hirsch IB. Insulin analogues. N Engl J Med 2005;352:174-83.
2. The Ministry of Health and Long-Term Care. Drugs funded by Ontario Drug Benefit (ODB) program. [E-Formulary] Toronto (ON): The Ministry; 2008. Available: www.health.gov.on.ca/english/providers/program/drugs/odbf-eformulary. html (accessed 2007 Feb. 13).
3. PPS pharma publication buyers guide. Ontario ed. Moncton (NB): Total Pricing Systems; 2007.
4. Cavallucci S. The top 200. What's making waves in prescription sales. Pharm Pract 2006;22(12):44-9. Available: www.pharmacygateway.ca/pdfs/ 2006/12/ppractice-top200-dec06.pdf (accessed 2007 Oct. 2).
5. Hauber A, Gale EAM. The market in diabetes. Diabetologia 2006;49:247-52.
6. Palmer AJ, Roze S, Valentine WJ, et al. The CORE Diabetes Model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin2004;20(Suppl 1):S5-26.
7. Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE Diabetes Model against epidemiological and clinical studies. Curr Med Res Opin 2004;20(Suppl 1): S27-40.
8. Canadian Optimal Medical Prescribing and Utilization Service. Optimal Therapy Report: Rapid-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes. Update of the CADTH Technical report No. 87. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2008. Available: http://cadth.ca/media/compus/reports/compus-Rapid- Acting-Insulin-Analogues-Report-Clinical=Outcomes.pdf (accessed 2008 Apr. 9).
9. Canadian Optimal Medical Prescribing and Utilization Service. Optimal Therapy Report: Rapid-acting insulin analogues for the treatment of diabetes mellitus: meta-analyses of clinical outcomes. Update of the CADTH Technical report No. 92. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2008. Available: http://cadth.ca/media/compus/reports/compus-Long- Acting-Insulin-Analogs-Report-Clinical-Outcomes.pdf (accessed 2008 Apr. 9).
10. Singh SR, Ahmad F, Lal A, et al. Efficacy and safety of insulin analogues for the management ofdiabetes mellitus: a meta-analysis. CMAJ2009;180: 385-97.
11. Canadian Optimal Medical Prescribing and Utilization Service. Optimal Therapy Report: An economic evaluation of insulin analogues for the treatment of patients with type 1 and type 2 diabetes mellitus in Canada. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2008. Available: http://cadth.ca/media/compus/reports/compus-Economic-IA-Report.pdf (accessed 2008Apr. 11).
12. Guidelines for the economic evaluation of health technologies: Canada. 3rd ed. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2006. Available: www.cadth.ca/media/pdf/186-EconomicGuidelines-e.pdf (accessed 2007 Feb. 9).
13. O'Reilly D, Hopkins R, Blackhouse G, et al. Development of an Ontario Diabetes Economic Model (ODEM) and application to a multidisciplinary primary care diabetes management program. Hamilton (ON): Program for Assessment of Technology in Health (PATH); 2006. Available: www.path-hta.ca/diabetes.pdf (accessed 2007 Jul. 12).
14. Hart HE, Redekop WK, Berg M, et al. Factors that predicted change in health-related quality of life were identified in a cohort of diabetes mellitus type 1 patients. J Clin Epidemiol2005;58:1158-64.
15. Ray JA, Valentine WJ, Secnik K, et al. Review of the cost of diabetes complications in Australia, Canada, France, Germany, Italy and Spain. Curr Med Res Opin 2005; 21:1617-29.
16. Manns B, Tonelli M, Shrive F, et al. Sevelamer in patients with end-stage renal disease: a systematic review and economic evaluation. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2006. Available: www.cadth.ca/media/pdf/HTA-349-sevelamer-tr-e.pdf (accessed 2007 Jul. 20).
17. Manns B, Johnson JA, Taub K, et al. Quality of life in patients with end-stage renal disease over time: the impact of dialysis modality and other important determinants [working paper 02-05]. Edmonton (AB): Institute of Pharmaco-Economics; 2002 Available: www.ihe.ca/documents/2002-05paper.pdf (accessed 2007 Jul 23).
18. Health costing in Alberta: 2006 annual report. Edmonton (AB): Alberta Health and Wellness; 2006. Available: www.health.gov.ab.ca/resources/ publications/Health-Costing-2006.pdf (accessed 2007 Feb. 14).
19. Caro J, Migliaccio-Walle K, Ishak KJ, et al. The morbidity and mortality following a diagnosis of peripheral arterial disease: long-term follow-up of a large database. BMC Cardiovasc Disord2005;5:14.
20. O'Brien JA, Patrick AR, Caro JJ. Cost of managing complications resulting from type 2 diabetes mellitus in Canada. BMC Health Serv Res 2003;3:7.
21. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993;329:977-86.
22. Nathan DM, Cleary PA, Backhand JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643-53.
23. Ogden CL, Fryar CD, Carroll MD, et al. Mean body weight, height, and body mass index, United States 1960-2002. Hyattsville (MD): US Department of Health and Human Services, US Centers for Disease Control and Prevention, National Center for Health Statistics; 2004. Available: www.cdc.gov/nchs/data/ad/ad347. pdf (accessed 2007 July 10).
24. National Health and Nutrition Examination Survey 1999-2000. Hyattsville (MD): National Centre for Health Statistics; 2007. Available: www.cdc.gov/nchs/data/nhanes/spq-di.pdf (accessed 2008 Nov. 26).
25. Consumer price index. The Daily. Ottawa (ON). Statistics Canada; 2008. Available: www.statcan.ca/Daily/English/080219/d080219a.htm (accessed 2008 Jun. 20).
26. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the economic evaluation of health care programmes. 3rd ed. Oxford (UK): Oxford University Press; 2005.
27. Berger ML, Bingefors K, Hedblom EC, et al., editors. Health care cost, quality, and outcomes: ISPOR book of terms. Lawrenceville (GA): International Society for Pharmacoeconomics and Outcomes Research; 2003.
28. EQ-5D: a standardised instrument for use as a measure of health outcome. Rotterdam (The Netherlands): Euroqol; 2007. Available: www.euroqol.org (accessed 2008 Nov. 27).
29. Sullivan PW, Ghushchyan V. Preference-based EQ-5D index scores for chronic conditions in the United States. Med Decis Making 2006;26:410-20.
30. Sullivan PW, Lawrence WF, Ghushchyan V. A national catalog of preference-based scores for chronic conditions in the United States. Med Care 2005;43:736-49.
31. Feeny D. As good as it gets but good enough for which applications? Med Decis Making 2006;26:307-9.
32. Coffey JT, Brandle M, Zhou H, et al. Valuing health-related quality of life in diabetes. Diabetes Care 2002;25:2238-43.
33. Calculating the US population-based EQ-5D index score. Rockville (MD): Agency for Healthcare Research and Quality; 2005. Available: www.ahrq.gov/rice/EQ5Dscore.htm (accessed 2007 Oct. 10).
34. Understanding emergency department wait times: How long do people spend in emergency departments in Ontario? Ottawa (ON): Canadian Institute for Health Information; 2007. Available: www.cihi.ca/cihiweb/en/downloads/ emergency-de-partment-wait-times-epdf (accessed 2008 Jan. 18).
35. PHARMAC responds on long-acting insulin analogues. N Z Med J 2005;118: U1716.
36. Home PD, Hallgren P, Usadel KH, et al. Pre-meal insulin aspart compared with pre-meal soluble human insulin in type 1 diabetes. Diabetes Res Clin Pract 2006; 71:131-9.
37. Henderson JN, Allen KV, Deary IJ, et al. Hypoglycaemia in insulin-treated type 2 diabetes: frequency, symptoms and impaired awareness. Diabet Med 2003;20: 1016-21.
38. Ahern J, Tamborlane WV. Steps to reduce the risks of severe hypoglycemia. Diabetes Spectr1997;10:39-41.
39. Hypoglycaemia. In: Diabetes network information. [Web site of NHS Dumfries & Galloway]. Available: www.dgdiabetes.scot.nhs.uk/icp/icptype1/ hypos.shtml (accessed 2008 Jan. 18).
40. Haak T, Tiengo A, Draeger E, et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005;7:56-64.
41. Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin 2006; 22:1523-34.
42. Davis RE, Morrissey M, Peters JR, et al. Impact of hypoglycaemia on quality of life and productivity in type 1 and type 2 diabetes. Curr Med Res Opin 2005;21: 1477-83.
43. Leiter LA, Yale JF, Chiasson JL, et al. Assessment of the impact of fear of hypo-glycemic episodes on glycemic and hypoglycemia management. Can J Diabetes 2005;29:186-92.
44. Levy RA, Christensen T, Bavinton H, et al. Estimating health related quality of life from hypoglycemia elicited from non-diabetic respondents in Canada [abstract no. 1205-P]. American Diabetes Association Annual Meeting; 2007 Jun 22-26; Chicago.
45. Matza LS, Boye KS, Yurgin N, et al. Utilities and disutilities for type 2 diabetes treatment-related attributes. Qual Life Res2007;16:1251-65.
46. Briggs AH, Wonderling DE, Mooney CZ. Pulling cost-effectiveness analysis up by its bootstraps: a non-parametric approach to confidence interval estimation. Health Econ 1997;6:327-40.
47. Briggs AH, Gray AM. Handling uncertainty in economic evaluations of healthcare interventions. BMJ1999;319:635-8.
48. Briggs A, Claxton K, Sculpher M. Decision modelling for health economic evaluation [Handbooks in Health Economic Evaluation series]. Toronto (ON): Oxford University Press; 2006.
49. Laupacis A, Feeny D, Detsky AS, et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ1992;146:473-81.
50. Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life-year: in search of a standard. Med Decis Making 2000;20:332-42.
51. Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. BMJ2004;329:224-7.
52. Ohinmaa A, Jacobs P, Simpson S, et al. The projection of prevalence and cost of diabetes in Canada: 2000 to 2016. Can J Diabetes2004;28(2):1-8.
53. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-53.
54. Briggs A, Sculpher M. An introduction to Markov modelling for economic evaluation. Pharmacoeconomics1998;13:397-409.
55. Lassere MN, Johnson KR, Boers M, et al. Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema. J Rheumatol 2007;34:607-15.
56. Ewart RM. The case against aggressive treatment of type 2 diabetes: critique of the UK prospective diabetes study. BMJ2001;323:854-8.
57. Rosen CJ. The rosiglitazone story - lessons from an FDA Advisory Committee meeting. N Engl J Med2007;357:844-6.
58. Richter B, Bandeira-Echtler E, Bergherhoff K, et al. Rosiglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;(3)CD006063.
59. Grima DT, Thompson MF, Sauriol L. Modelling cost effectiveness of insulin glargine for the treatment of type 1 and 2 diabetes in Canada. Pharmacoeconomics 2007;25:253-66.
60. Guidance on the use of long-acting insulin analogues for the treatment of diabetes-insuling glargine [technology appraisal guidance no 53]. London (UK): National Institute for Clinical Excellence (NICE); 2002. Available: www.nice.org.uk/download.aspx?o=TA053guidance (accessed 2006 Sep. 28).
61. Sculpher MJ, Pang FS, Manca A, et al. Generalisability in economic evaluation studies in healthcare: a review and case studies. Health Technol Assess2004;8:iii-iv, 1-192.